About IQVIA South Korea
We are IQVIA, The Human Data Science Company
Healthcare is an industry designed to help humans. As a global community, we continuously invest and commit to advancing human health. To deliver value and real outcomes. To rise to the challenge to find the next breakthrough by making the most of increasingly limited resources.
We are inspired by the potential and propelled by the possibilities. We share the vision to drive healthcare forward. To see how we can help accelerate progress and achievements. Others are developing these medical breakthroughs. We do our part by using breakthroughs in insights, technology and human intelligence to reimagine and deliver ways to help make them a reality.
It’s bigger than better clinical trials. Or advances in technologies and analytics. Or faster insights. It’s about unleashing the power of human data science. And that is why IMS Health and Quintiles have come together to be IQVIA, the Human Data Science Company.
Motivated by the industry we help, we’re committed to providing solutions that enable life sciences companies to innovate with confidence, maximize opportunities, and, ultimately, drive human health outcomes forward.
IQVIA Korea offers local and multinational clients a comprehensive portfolio of offerings across the clinical-commercial spectrum to help biopharmaceutical, medical device and other healthcare organizations succeed.
South Korea ranked 13th in the world pharmaceutical market in 2016. Both Western and Asian medicine are offered at over 80,000 healthcare centers throughout the country. The market is highly fragmented, with about 300 pharmaceutical companies and 1,800 wholesalers. According to the IMS Health Market Prognosis March 2017, the Korean pharmaceutical market is forecast to grow at a compound annual growth rate (CAGR) of 4.5% between 2016 and 2021.
There is an increasing demand for change and innovation in the South Korean healthcare environment surrounding its pharmaceutical industry. South Korea’s rapidly aging population, coupled with the government’s plans to expand National Health Insurance (NHI) coverage for four major chronic disease areas is expected to drive growing demands for healthcare services and drugs over the next five years. The government’s implementation of new policies such as the disclosure of big data is also expected to bring a seismic change in healthcare business and marketing.
Companies will face greater sales challenges as new regulatory measures take effect. The Health Insurance Review and Assessment Service (HIRA) and National Health Insurance Service (NHIS) play key roles in setting up reimbursement guidelines, sophisticated monitoring activities and pricing policy for medicines.
IQVIA Korea pays close attention to the challenges and opportunities arising from rapid development and change under such a complex pharma industry situation. Based on precise diagnosis of the current situations and issues facing the industry, IQVIA Korea strives to provide solutions tailored to the needs of our clients. These solutions will help our clients develop innovative ideas and foster their global networks so that our clients will be able to come up with effective global strategies.
We are dedicated to being the best partner for smarter healthcare in today’s highly competitive and complex environment. IQVIA Korea will continue to help our clients achieve a success in their businesses and contribute to the advancement of the Korean healthcare system by fully utilizing the valuable experience and insights gained from our cutting-edge information, technology and services.